Articles From: Transgenomic Announces Commencement of Public Offering of Common Stock to Transocean Files 8K - Other Events


2015/2/26
Transgenomic, Inc. (NASDAQ: TBIO) today announced that it intends to offer shares of the company’s common stock and corresponding warrants to purchase shares of the company’s common stock in an underwritten public offering.
Sign-up for Transgenomic Announces Commencement of Public Offering of Common Stock investment picks
2015/1/14
Transgenomic, Inc. (NASDAQ: TBIO) , a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that the commercial launch of its Multiplexed ICE COLD-PCR TM (MX-ICP) product line is scheduled in the first quarter of 2015.
Sign-up for Transgenomic Announces Q1 2015 Launch of Its Multiplexed Ice Cold-PCRTM Technology That Enables Wide Use of Liquid Biopsies and Personalized Medicine investment picks
2015/1/8
Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that Chief Executive Officer Paul Kinnon will give a corporate presentation at the 8 th Annual OneMedForum Conference being held at the Marriott Marquis Hotel in San Francisco, CA.
Sign-up for Transgenomic to Present at OneMedForum San Francisco 2015 Conference investment picks
2015/1/9
http://www.ccnmatthews.com/logos/20090904-tgl_logo.jpg CALGARY, ALBERTA --
Sign-up for TransGlobe Energy Corporation 2015 Guidance and Corporate Update investment picks
2015/2/11
http://www.ccnmatthews.com/logos/20090904-tgl_logo.jpg CALGARY, ALBERTA --
Sign-up for TransGlobe Energy Corporation Announces 2014 Year-End Reserves, Yemen Write Down and Export Marketing Update investment picks
2015/3/3
http://www.ccnmatthews.com/logos/20090904-tgl_logo.jpg CALGARY, ALBERTA --
Sign-up for TransGlobe Energy Corporation Announces Declaration of Quarterly Dividend investment picks
2015/2/25
Transition Networks, Inc. , the fiber access technology expert, a wholly owned subsidiary of Communications Systems, Inc. (NASDAQ-GM: JCS), today announced a new family of hardened Ethernet serial device servers with data encryption capabilities that improve security and scalability for connecting industrial equipment to Ethernet networks in harsh environments.
Sign-up for Transition Networks Expands Hardened Ethernet Product Family with Three New Serial Device Servers investment picks
2015/3/2
Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease Canada NewsWire TORONTO , March 2, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited ("TTIL") completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD"). The objectives of the Phase 2 clinical study ("Harmony AD Study") are to evaluate the efficacy, safety and tolerability of ELND005 over 12 weeks of treatment in patients with mild to severe AD, who are experiencing at least moderate levels of agitation/aggression. The randomized, double-blind, placebo-controlled study has enrolled 350 AD patients at 69 clinical sites
Sign-up for Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease investment picks
2015/3/2
TORONTO , March 2, 2015 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited ("TTIL") completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD").  The objectives of the Phase 2 clinical study ("Harmony AD Study") are to evaluate the efficacy, safety and tolerability of ELND005 over 12 weeks of treatment in patients with mild to severe AD, who are experiencing at least moderate levels of agitation/aggression. The randomized, double-blind, placebo-controlled study has enrolled 350 AD patients at 69 clinical sites in the United States , Canada , Spain and the United Kingdom.
Sign-up for Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease investment picks
2015/2/9
Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results Canada NewsWire TORONTO , Feb.
Sign-up for Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results investment picks
2015/2/9
TORONTO , Feb.
Sign-up for Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results investment picks
2015/2/18
Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares Canada NewsWire TORONTO , Feb.
Sign-up for Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares investment picks
2015/2/18
TORONTO , Feb.
Sign-up for Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares investment picks
2015/2/12
Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares Canada NewsWire TORONTO , Feb.
Sign-up for Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares investment picks
2015/2/12
TORONTO , Feb.
Sign-up for Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares investment picks
2015/2/11
Transition Therapeutics Inc. Announces Public Offering of Common Shares Canada NewsWire TORONTO , Feb.
Sign-up for Transition Therapeutics Inc. Announces Public Offering of Common Shares investment picks
2015/2/11
TORONTO , Feb.
Sign-up for Transition Therapeutics Inc. Announces Public Offering of Common Shares investment picks
2015/2/5
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2015 Financial Results on Monday, February 9th, at 4:30 P.M. EST Canada NewsWire TORONTO , Feb.
Sign-up for Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2015 Financial Results on Monday, February 9th, at 4:30 P.M. EST investment picks
2015/2/19
Transition Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference Canada NewsWire TORONTO , Feb.
Sign-up for Transition Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference investment picks
2015/2/19
TORONTO , Feb.
Sign-up for Transition Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference investment picks
2014/12/8
TORONTO , Dec.
Sign-up for Transition Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference investment picks
2014/12/19
SOUTH PLAINFIELD, N.J. , Dec.
Sign-up for Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I investment picks
2015/1/8
TransMontaigne Partners L.P. (NYSE:TLP) announced today that it declared a distribution of $0.665 per unit for the period from October 1, 2014 through December 31, 2014.
Sign-up for TransMontaigne Partners L.P. Announces Quarterly Distribution investment picks
2014/12/8
TransMontaigne Partners L.P. (NYSE:TLP) today announced that management will participate in the Wells Fargo Securities Research, Economics & Strategy 2014 Annual Energy Symposium at The Waldorf Astoria in New York City on December 10, 2014.
Sign-up for TransMontaigne Partners L.P. to Present at Wells Fargo Securities Research, Economics & Strategy 2014 Energy Symposium in New York City investment picks
2015/2/15
By Anjie Zheng And Andrew Peaple Oil-services company Transocean Ltd.
Sign-up for Transocean CEO and President Steps Down -- Update investment picks
2015/2/15
By Anjie Zheng Transocean Ltd.
Sign-up for Transocean CEO and President Steven Newman Steps Down investment picks
2015/2/17
Transocean Ltd.
Sign-up for Transocean Files 8K - Changes Executive Management investment picks
2015/2/6
Transocean Ltd.
Sign-up for Transocean Files 8K - Other Events investment picks
2015/2/17
Transocean Ltd.
Sign-up for Transocean Files 8K - Other Events investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Transgenomic Announces Commencement of Public Offering of Common Stock to Transocean Files 8K - Other Events
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent